In both MCI and dementia stages of AD, the levels of plasma ApoA1 are decreased compared to cognitive normal subjects in most studies, with few exceptions, while CSF ApoA1 is reported as unchanged or decreased between disease stages across different studies [16]. This evidence concerns the gene APOA1 and Alzheimer disease.